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Head and neck cancer is the sixth leading cancer by incidence worldwide. Unfortunately, drug resistance and relapse are the
principal limitations of clinical oncology for many patients, and the failure of conventional treatments is an extremely
demoralizing experience. It is therefore crucial to find new therapeutic targets and drugs to enhance the cytotoxic effects of
conventional treatments without potentiating or offsetting the adverse effects. Melatonin has oncostatic effects, although the
mechanisms involved and doses required remain unclear. The purpose of this study is to determine the precise underlying
mitochondrial mechanisms of melatonin, which increase the cytotoxicity of oncological treatments, and also to propose new
melatonin treatments in order to alleviate and reverse radio- and chemoresistant processes. We analyzed the effects of
melatonin on head and neck squamous cell carcinoma (HNSCC) cell lines (Cal-27 and SCC-9), which were treated with 0.1, 0.5,
1, and 1.5mM melatonin combined with 8Gy irradiation or 10 μM cisplatin. Clonogenic and MTT assays, as well as autophagy
and apoptosis, involving flow cytometry and western blot, were performed in order to determine the cytotoxic effects of the
treatments. Mitochondrial function was evaluated by measuring mitochondrial respiration, mtDNA content (RT-PCR), and
mitochondrial mass (NAO). ROS production, antioxidant enzyme activity, and GSH/GSSG levels were analyzed using a
fluorometric method. We show that high concentrations of melatonin potentiate the cytotoxic effects of radiotherapy and
CDDP in HNSCC, which are associated with increased mitochondrial function in these cells. In HNSCC, melatonin induces
intracellular ROS, whose accumulation plays an upstream role in mitochondria-mediated apoptosis and autophagy. Our
findings indicate that melatonin, at high concentrations, combined with cisplatin and radiotherapy to improve its effectiveness,
is a potential adjuvant agent.
1. Introduction
Head and neck cancer, which is the sixth leading cancer by
incidence worldwide, with more than 300,000 mortalities
annually [1], has become a major health burden, especially
as cell resistance to radio and chemotherapy develops.
Radiotherapy (RT), which is one of the most commonly
used tumor treatments [2], damages biomolecules, such as
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proteins and lipoids, particularly DNA, resulting in the termi-
nation of cell division and proliferation and even in cell necrosis
or apoptosis. However, many unwanted effects, such as radio-
resistance, can complicate the prognosis [2]. One way to over-
come these problems is to increase RT effectiveness by using
radiosensitizers to enhance tumor cell radiosensitivity [3].
On the other hand, cisplatin (CDDP), one of the most
commonly used chemotherapeutic agents, is the treatment of
choice for most head and neck squamous cell carcinoma
(HNSCC) patients. CDDP is a highly reactive molecule that
binds to RNA, DNA, and proteins to form different types of
adducts. CDDP also induces mitochondria-dependent reac-
tive oxygen species (ROS) formation which contributes to
cell-killing processes by enhancing the damaging effect of
drugs on nuclear DNA (nDNA) [4]. However, the high inci-
dence of chemoresistance and its many side effects limit the
clinical usefulness of CDDP as an anticancer treatment [5,
6]. Therefore, new anticancer therapeutic strategies to attenu-
ate cytotoxicity in normal tissues and to prevent or reverse
the development of radio and chemoresistance are required.
Mitochondria have a major impact on cancer cells due to
the source of ATP, their capacity to produce ROS, and their
central position in the apoptosis signaling pathway [7, 8].
Although very low supraphysiological levels of mitochon-
drial ROS can promote tumor diversification by favoring
mutagenesis [9], ROS overproduction, leading to severe
mitochondrial dysfunction, is generally incompatible with
tumor progression, which promotes cell death and cellular
senescence [10]. Thus, given the impact of mitochondrial
metabolism on the treatment response, a considerable effort
has been devoted to developing a chemo/radiosensitization
strategy involving the development of molecules to target
mitochondria [9, 11]. However, one of the main drawbacks
of this strategy of targeting mitochondria to kill malignant
cells or to increase their sensitivity to treatment is that
multiple immune effector cells bear a remarkable meta-
bolic similarity to cancer cells [9, 12].
Although the indoleamine melatonin (N-acetyl-5-methox-
ytryptamine) is synthetized in the pineal gland, it is produced
by many other organs at even higher concentrations [13].
Melatonin has a variety of biological features including
anti-inflammatory and antioxidant activity, as well as immune
system regulation mechanisms. It also has oncostatic effects,
although the mechanisms involved remain unclear [14–17].
Our previous studies show that melatonin enhances the cyto-
toxic effects of rapamycin in HNSCC cells [18]. However, little
data exist on themechanisms ofmelatonin involved in increas-
ing chemo- and radiotherapy-induced cancer cell injury or cell
death and in simultaneously decreasing its adverse effects.
In this study, we first explore the potential capacity of
melatonin to enhance the antitumor effects of irradiation
and CDDP on HNSCC. We then investigate the precise
underlying mitochondrial mechanisms which enhance
the cytotoxic effects of these treatments on HNSCC.
2. Materials and Methods
2.1. Cell Culture. Human tongue squamous carcinoma cell
lines Cal-27 and SCC-9, obtained from the American Type
Culture Collection (ATCC® CRL2095™ and CRL1629™,
respectively) in the Cell Bank of the Centre for Scientific
Instrumentation at the University of Granada, were cultured
in a humidified atmosphere (5% CO2 and 95% air at 37
°C).
The cells were cultured in high-glucose Dulbecco’s modified
Eagle’s medium (DMEM), GlutaMAX supplemented with
10% fetal bovine serum, and 2% antibiotic-antimycotic
(Fisher Scientific, Madrid, Spain) for Cal-27 and were grown
in DMEM-F12 Nutrient Mixture Ham medium (1 : 1) con-
taining 2mM L-glutamine (Fisher Scientific, Madrid, Spain)
and 0.5mM sodium pyruvate supplemented with 10% FBS,
0.4μg/mL hydrocortisone (Sigma-Aldrich, Madrid, Spain),
and 2% antibiotic-antimycotic for SCC-9.
Melatonin stock solution (Fagron Ibérica S.A.U., Ter-
rasa, Spain) was prepared in 15% propylene glycol (PG)
(VWR, Radnor, PA, USA). Cells were grown to 60%-70%
confluence and serum starved for 24 hours. Then, cells were
treated with and without melatonin (100, 500, 1000, and
1500μM). After 48 hours, cells were exposed to 8Gy
irradiation using a cesium-137 gamma radiation source
(8Gy/min) or treated with 10μM CDDP for 5 hours (Sig-
ma-Aldrich, Madrid, Spain). Cells of the control group were
treated with a vehicle (PG 15%). Assays were performed 48
hours after irradiation and CDDP treatment.
2.2. Colony Formation Assay. Cells were plated into 6-well
plates and allowed to attach overnight. They were treated
with melatonin and, after 48 hours, were irradiated or treated
with CDDP. Colonies were allowed to grow for 2 weeks to
form colonies of at least 50 cells. Finally, the medium was
removed, the cells were fixed, and the colonies were then
stained with 2.3% crystal violet and counted [18].
2.3. Cell Proliferation Assay. Cell viability was determined
using an MTT assay (Life Technologies, Madrid, Spain)
based on the reduction of yellow 3-(4,5-dimethylthiazo-
l-2-yl)-2,5-diphenyltetrazolium bromide to purple formazan
by mitochondrial dehydrogenases. Cells were plated into
96-well plates, and the assay was performed according to
the manufacturer’s instruction.
2.4. Apoptosis. Apoptosis was measured by flow cytometry
using FITC Annexin V staining (Immunostep, Salamanca,
Spain). Cells were treated as described above. Finally, cells
were collected, washed with cold PBS, and then simulta-
neously stained with FITC-labeled annexin V and PI and
analyzed by flow cytometry in a Becton Dickinson FACS-
Canto II cytometer (Madrid, Spain).
2.5. Western Blot Analysis. Protein extraction and western
blot analyses were performed as described previously [19].
Bax (sc-526), Bcl-2 (sc-492), ATG12 C6 (sc-271688), and
GAPDH (sc-32233) antibodies and a mouse anti-goat
IgG-HRP secondary antibody (sc-2354) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA),
NIX from Sigma-Aldrich (Madrid, Spain), and HRP goat
anti-mouse IgG from BD Pharmingen™ (San Jose, CA,
USA). The proteins were visualized using a Western
Lightning Plus-ECL chemiluminescence kit (PerkinElmer,
Billerica, MA, USA) according to the manufacturer’s
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protocol. Images were analyzed using the Kodak Image Station
2000R (Eastman Kodak Company, Rochester, NY, USA).
Protein band intensity was normalized to GAPDH, and data
were expressed in percentage terms relative to controls.
2.6. Mitochondrial Respiration. The oxygen consumption
rate (OCR), an indicator of mitochondrial respiration
under typical in vitro cell culture conditions [18], was
determined using the Seahorse Extracellular Flux (XFe24)
analyzer (Seahorse Bioscience, MA, USA). The day before
the experiment, live treated cells (exclusion by trypan blue)
were seeded in DMEM in 24-well culture plates at a density
of 8 · 104 cells/well and were allowed to adhere overnight in
a cell culture incubator in order to minimize division or
death. Cell growth and health were monitored using a
microscope following the manufacturer’s instructions, and
the assay was only performed if the cells under all condi-
tions formed a consistent monolayer. Subsequently, the
assays were initiated by replacing the media with assay
medium (Seahorse Bioscience), and the cells were equili-
brated for 1 h at 37°C without CO2. The microplate was
then placed into the XFe24 instrument to measure the
OCR and free protons in the medium. Basal OCR was
measured three times and plotted as a function of cells
under the basal condition, followed by the sequential addi-
tion of oligomycin 1mM. Subsequently, carbonyl cyanide
4-(trifluoromethoxy)phenylhydrazone (FCCP) 0.5mM was
added in two injections (1mM in total). Finally, roteno-
ne/antimycin A (1mM) was injected. OCR was measured
throughout the different injections of the test compounds.
The progress curve was annotated to show the relative
contribution of basal, ATP-linked, and maximal oxygen
consumption after the addition of FCCP, and the reserve
capacity of the cells. OCR values were normalized to
cell number.
2.7. Determination of Mitochondrial Mass. We measured
mitochondrial mass using acridine orange 10-nonyl bromide
(NAO; Invitrogen Life Technologies, Madrid, Spain), which
specifically binds to cardiolipin at the inner mitochondrial
membrane, according to the protocol described by Shen
et al. [18]. Fluorescence was read by an FLx800 microplate
fluorescence reader (BioTek Instruments Inc., Winooski,
VT, USA) at excitation 485nm and emission 530 nm.
2.8. Mitochondrial DNA Quantification. Human mitochon-
drial DNA (mtDNA) was quantified by real-time PCR
using the Stratagene Mx3005P Real-Time PCR System
(Agilent Technologies Inc., CA, USA). We used primers
and probes for the human 12S gene (mtDNA) and 18S.
The mtDNA values were normalized to nDNA data
(mtDNA/nDNA ratio).
2.9. Measurement of ROS Production. ROS production was
measured using the 2′-7′-dichlorofluorescin diacetate
(DCFH-DA) probe (Sigma-Aldrich, Madrid, Spain). Cells
were seeded in 96-well culture plates. Then, the cells were
incubated with 100μM DCFH-DA in culture medium with-
out phenol red for 30min at 37°C and then rinsed with PBS
and filled with Krebs-Ringer bicarbonate buffer. ROS levels
were measured in a multiwell plate reader spectrofluorometer
(BioTek Instruments Inc., Winooski, VT, USA) for 45
minutes each 5 minutes at 485nm to excitation and 530nm
to emission [18].
2.10. Measurement of GSH and GSSG Levels and GPx
Activity. To measure glutathione (GSH) and glutathione
disulfide (GSSG), we used an established fluorometric
method using a microplate fluorescence reader (PowerWa-
veX FLx800; BioTek Instruments Inc., Winooski, VT) [20].
We spectrophotometrically measured glutathione peroxi-
dase (GPx) activity in a UV spectrophotometer (model
UV-1603; Shimadzu Deutschland GmBH, Duisburg,
Germany) [21].
2.11. Statistical Analysis. Statistical analyses were performed
using GraphPad Prism 6 scientific software (GraphPad Soft-
ware Inc., La Jolla, CA) and one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison tests.
Data were expressed as the mean ± SEM of a minimum of
three independent experiments. A P value of <.05 was con-
sidered statistically significant.
3. Results
3.1. Melatonin Enhances the Cytotoxic Effects of Irradiation
and CDDP in HNSCC. To evaluate the biological effect of
melatonin on HNSCC sensitivity to irradiation and CDDP
treatments, the clonogenic capacity and viability of both
Cal-27 and SCC-9 were analyzed. As shown in
Figures 1(a)–1(c), treatment with melatonin alone and in
combination with irradiation significantly inhibited colony
formation and resulted in a notable decrease in the colony
ratio in a dose-dependent manner as compared to control
or to irradiation alone. In fact, melatonin alone totally
blocked colony growth. However, CDDP displayed a
greater capacity than irradiation to decrease clonogenic
formation (Figures 1(f)–1(h)).
MTT assays of both cell lines were also performed. In
line with the inhibition of clonogenic capacity, melatonin
markedly decreased cell viability in the irradiated cells in
a dose-dependent manner, especially at doses 500 and
1500μM, as compared to control and irradiation alone
(Figures 1(d)–1(e)), although SCC-9 cells were found to
be more resistant than Cal-27 cells to the treatments. Sur-
prisingly, 100μM melatonin did not significantly reduce
viability, particularly in SCC-9 (Figures 1(d)–1(e)). On the
other hand, melatonin significantly decreased cell viability
in the CDDP-treated cells in a dose-dependent manner as
compared to the control and CDDP alone (Figures 1(i)–
1(j)). SCC-9 cells were also more resistant to melatonin
exposure than Cal-27 cells. The results were more signifi-
cant for Cal-27 cells, which were therefore used in subse-
quent experiments.
3.2. Melatonin Enhances the Apoptotic Effects of Irradiation
and CDDP in HNSCC. Since the MTT assay is a quantitative
measure of cell proliferation and a decrease in proliferating
cells can be caused by either cell death or halted/slow
proliferation, apoptotic cell death was therefore evaluated.
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Early apoptotic cells showed an annexin V-FITC+/PI-
staining pattern, while late apoptotic cells exhibited an
annexin V-FITC+/PI+ pattern (Figure 2) due to plasma
membrane integrity loss [22]. In the combined melatonin/ir-
radiation treatment, melatonin increased early apoptosis,
which reached a maximum level at 1500μM as compared
to that of the control (Figures 2(a)–2(b)). However, irradia-
tion alone enhanced late apoptosis but did not affect early
apoptosis (Figures 2(a)–2(b)). This indicates that melatonin
increases the acute cytotoxicity of irradiation. By contrast,
treatment with CDDP alone did not increase apoptosis
pathway activation (Figures 2(g)–2(h)), while the combined
treatment increased late apoptosis at a melatonin dose of
500μM (Figure 2(h)).
Apoptosis initiation is associated with the translocation
of the inactive form of Bax from the cytoplasm to the mito-
chondria and suppression of the prosurvival protein Bcl-2.
Bax and Bcl-2 protein expression was explored using west-
ern blot analysis. In line with the results above, Bcl-2 levels
were clearly attenuated by 500 and 1500μMmelatonin doses
combined with irradiation, which increased the Bax/Bcl-2
ratio, with a maximum effect being observed at 1500μM
(Figures 2(c)–2(f)). Moreover, melatonin combined with
CDDP increased the Bax/Bcl-2 ratio more than when com-
bined with irradiation despite using a lower concentration
of melatonin (1000μM vs. 1500μM) (Figures 2(i)–2(l)).
These data indicate that melatonin combined with CDDP




























































































































































































































































































































































































































































Figure 1: Melatonin increases the cytotoxic effects of irradiation (IR) and CDDP in HNSCC cell lines Cal-27 and SCC-9. Clonogenic assay of
cells exposed to IR (a–c) or CDDP (f–h) and viability of cells exposed to IR (d, e) or CDDP (i, j). Treatment groups include the control
(vehicle), IR (8Gy), CDDP 10μM, melatonin (aMT) 1000 or 1500μM, and CDDP or IR plus aMT 100, 500, 1000, or 1500μM. n = 6 per
group. Data are presented as mean ± SEM. ∗∗P < 01 and ∗∗∗P< 001 vs. the control, #P < 05 and ###P < 001 vs. the IR- or CDDP-treated
group, δP < 05 and δδδP < 001 vs. IR+aMT 100, and $P < 05 and $$$P < 001 vs. IR+aMT 500.
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3.3. Enhancement of Mitochondrial Changes by Melatonin.
Mitochondria are critically involved in controlling regulated
cell death triggered by different cancer treatments [9], and
several metabolic aspects of the mitochondrial biology also
influence therapeutic responses [23]. As melatonin regulates
mitochondrial homeostasis [24, 25], we hypothesized that
melatonin potentiates the cytotoxicity of irradiation and
CDDP treatments modifying mitochondrial function. We
first determined the oxygen consumption rate (OCR), which
is an indicator of mitochondrial oxidative phosphorylation
activity and ATP production. While measuring oxygen con-
sumption rates, we sequentially added oligomycin, FCCP,
and a combination of rotenone and antimycin to the cells
to assess electron transport chain integrity (Figures 3(a)–
3(k)). Irradiated Cal-27 cells exhibited a significant increase
in basal respiration (Figure 3(b)) and in the maximal respi-
ratory capacity of the electron transport system (ETS)



































































































































































































































































































































































































































































































































































































































































































































Figure 2: Combined treatment with melatonin and IR or CDDP increases apoptotic cell death in the HNSCC cell line Cal-27. Apoptosis was
analyzed by flow cytometry. (a–g) Representative plots showing the redistribution of phosphatidylserine (annexin V staining) in the presence
of propidium iodide (PI). The bottom right quadrant represents the percentage of early apoptotic cells (annexin V+/PI-), whereas the top
right quadrant represents the percentage of late apoptotic cells (annexin V+/PI+). Statistical analysis of early and late apoptosis of cells
exposed to IR (b) and CDDP (h), respectively. Western blot analysis (f–l) and densitometric quantification of Bax (c–i) and Bcl-2 (d–j)
and the Bax/Bcl-2 ratio (e–k) in cells exposed to IR or CDDP, respectively. Treatment groups include the control (vehicle), IR (8Gy),
CDDP 10 μM, melatonin (aMT) 1000 or 1500 μM, and CDDP or IR plus aMT 100, 500, 1000, or 1500μM. n = 6 per group. Data are
presented as mean ± SEM. ∗P< 05, ∗∗P < 01, and ∗∗∗P< 001 vs. the control; #P< 05, ##P< 01, and ###P< 001 vs. the IR- or CDDP-treated
group; δP< 05, δδP< 01, and δδδP< 001 vs. IR+aMT 100; and $P< 05, $$P< 01, and $$$P< 001 vs. IR+aMT 500.
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an increase of ATP (Figure 3(d)) with no change in proton
leak (Figure 3(e)). Surprisingly, melatonin 1500μM caused
a decrease in the OCR as compared to melatonin 500μM
(Figures 3(b)–3(d)), suggesting defective mitochondrial
function at higher concentrations of melatonin. By contrast,
cells treated with CDDP alone or melatonin 100μM
showed a decrease in the OCR (Figures 3(l)–3(n)), while
melatonin doses of 500 and 1000μM rescued the OCR as
compared to the control. These results are in line with the
direct effect of CDDP on mitochondria which interferes
with mtDNA transcription, resulting in reduced mitochon-
drial function [26].
To further determine changes in mitochondria in the
presence of melatonin, we next analyzed mitochondrial
mass and mtDNA (Figures 3(f), 3(g), 3(p), and 3(q)). To


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3: Effects of combined treatment with melatonin and IR or CDDP on Cal-27 HNSCCmitochondria. Oxygen consumption rate (OCR)
(a, k), basal respiration (b, l), maximal respiratory capacity (ETS) (c, m), ATP production (d, n), and proton leak (e, o) in cells exposed to IR or
CDDP, respectively. Mitochondrial mass (NAO) (f, p), mtDNA (g, q), western blot analysis, and densitometric quantification of
ATG12-ATG5 (h, j, r, t) and NIX (i, j, s, t) in cells exposed to IR or CDDP, respectively. Treatment groups include the control (vehicle),
IR (8Gy), CDDP 10μM, melatonin (aMT) 1000 or 1500 μM, and CDDP or IR plus aMT 100, 500, 1000, or 1500μM. n = 6 per group.
Data are presented as mean ± SEM. ∗P< 05, ∗∗P< 01, and ∗∗∗P< 001 vs. the control; #P< 05, ##P< 01, and ###P< 001 vs. the IR- or
CDDP-treated group, δP< 05, δδP< 01, and δδδP< 001 vs. IR+aMT 100; $P< 05, $$P< 01, and $$$P< 001 vs. IR+aMT 500.
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Fluorescence data revealed that high concentrations of mel-
atonin significantly augmented mitochondrial mass com-
pared to the control, especially at 1500 and 1000μM, in
cells exposed to irradiation or CDDP (Figures 3(f)–3(p)).
Moreover, similar doses of melatonin increased the
mtDNA/nDNA ratio (Figures 3(g) and 3(q)), indicating
that melatonin significantly increases mtDNA.
In a previous study, we demonstrated that melatonin may
induce both apoptosis and autophagy in HNSCC [18]. We
determined the levels of autophagy-related proteins
ATG12-ATG5, as autophagy requires the covalent attachment
of protein Atg12 to protein ATG5 through an ubiquitin-like
conjugation system and the mitophagic marker NIX. The
combined melatonin and irradiation treatment increased
ATG12-ATG5 levels at all doses (Figures 3(h) and 3(j)) but
decreased NIX levels (Figures 3(i) and 3(j)). However, the
combination of melatonin and CDDP increased both
ATG12-ATG5 and NIX (Figures 3(r)–3(t)). These data indi-
cate that the combined melatonin and CDDP treatment, with
its higher toxicity, results in autophagy and mitophagy.
These results could denote a correlation between an
increase of mitochondrial activity induced by melatonin
and ROS production.
3.4. Enhancement of Oxidative Stress in the Presence of
Melatonin. To determine whether mitochondrial changes
correlate with an increase in ROS, we measured ROS gener-
ation intensity using the DCFH-DA probe (Figure 4(a)). We
observed a significant increase in intracellular ROS levels at
melatonin 1500μM in irradiated cells and, consequently,
an increase in the GSSG/GSH ratio (Figures 4(c)–4(e)).
Moreover, melatonin 500 and 1000μM resulted in a sharper
increase in ROS production in cells exposed to CDDP as
compared to irradiation (Figure 4(g)). However, the increase
in the GSSG/GSH ratio was only observed at 1000μM
(Figures 4(i)–4(k)), indicating that high doses of melatonin
increased glutathione synthesis (Figures 4(f) and 4(l)). A
parallel decrease in GPx activity was observed at the highest
concentration of melatonin, especially in cells treated with
CDDP (Figure 4(h)). However, at melatonin 100μM com-
bined with irradiation, we observed an increase in GPx activ-
ity (Figure 4(b)). These results are consistent with the lower
levels of ROS observed at melatonin 100μM as compared to
1500μM. These data suggest that mitochondria cause a
melatonin-induced ROS response in cancer cells which
enhances the cytotoxic effects of irradiation and CDDP. Fur-
thermore, despite being known to be a strong antioxidant,
previous studies have shown that melatonin increases ROS
production in tumor cells [18]. Thus, melatonin induces
apoptosis in HNSCC by generating intracellular ROS and
activating the mitochondrial pathway, thus increasing the
effect of irradiation and CDDP.
4. Discussion
Radio- and chemotherapeutic resistance remains the major
obstacle to successful cytotoxic therapy for human cancers.
After the failure of the usual treatments, following chemo-
or radiotherapy, even more distressing situations occur.
Therefore, finding a coadjuvant treatment to suppress or
reduce this resistance would represent a major advance
for both patients and the health system as a whole. On
the other hand, the treatments currently used usually pres-
ent a high degree of toxicity in healthy cells. In this study,
we demonstrate that melatonin significantly affects sensitiv-
ity to irradiation and CDDP in HNSCC, as reflected by
reduced cell proliferation and clonogenicity, as well as
apoptosis induction. Although the antitumor activity of
melatonin has been reported elsewhere [27–29], the poten-
tial mechanisms involved remain unclear. Despite all the
studies carried out, there are a disconcertingly large number
of possible mechanisms which could explain the oncostatic
effects of melatonin, involving almost as many mechanisms
as tumor types. This suggests that only epiphenomena of an
as yet unknown underlying mechanism of melatonin have
been observed [29, 30].
In this study, we not only demonstrate the role of
melatonin in improving the effects of irradiation and CDDP
antitumor treatment but also, more importantly, describe
the possible mechanisms involved in combined treatments
which enhance their anticancer properties.
Cancer cells display increased resistance to regulated cell
death, often due to alterations in the mitochondrial control
of this process [31]. It has been suggested that the ability of
most cancer cells to flexibly rewire their mitochondrial metab-
olism underlies multiple instances of chemoresistance [9].
Moreover, as melatonin has recently been shown to increase
neural stem cell differentiation due to increased mitochondrial
function [32], a similar mechanism could, in our view, occur
in tumor cells. We therefore hypothesize that melatonin raises
ROS production levels by increasing mitochondrial function
in tumor cells. Consequently, cellular differentiation is
expected to be caused by a change in cell metabolism, thereby
increasing tumor sensitivity to other drugs. In this study, we
provide, for the first time, evidence that the increase in irradi-
ation and CDDP cytotoxicity caused by melatonin is partly
due to enhanced mitochondrial function.
Our results show that melatonin-induced apoptosis
coincides with a significant upregulation of the proapoptotic
protein Bax and a downregulation of the antiapoptotic pro-
tein Bcl-2 on HNSCC. Bcl-2 overexpression is often associ-
ated with considerable cancer cell resistance to apoptosis
[33]. When the Bax/Bcl-2 ratio increases, the mitochondrial
permeability transition pore opens which, in turn, releases
apoptogenic mitochondrial proteins to activate caspases
which induce cell apoptosis [34]. Interestingly, the combined
melatonin and cisplatin treatment had higher cytotoxicity
than the combined treatment with irradiation. The main
bulk of irradiated cells may take longer to enter apoptosis
than those treated with CDDP. Other authors, such as Mir-
zayans et al. [35], have made a similar observation that dif-
ferent cancer cell lines such as HCT116, MCF7, and AT12
are markedly refractory to apoptosis in response to ionizing
radiation. In this regard, it is possible to broadly classify cell
death mechanisms into two classes: those occurring rela-
tively soon after irradiation and before cell division leading
to early cell death and those occurring comparatively late
or after division leading to late cell death. The vast majority
7Oxidative Medicine and Cellular Longevity
of proliferating normal and tumor cells die after a relatively
long period following irradiation, usually after attempting
mitosis one or more times [36]. As a result, alterations in a
particular gene may dramatically alter the levels of
radiation-induced apoptosis, without changing the overall
ability of the cell to survive [36]. In this case, cells die regard-
less of whether apoptosis is subsequently induced. On the
other hand, the cytotoxic effect is dependent on drug
concentrations, time of exposure, and time after exposure
[37]. Generally, CDDP induces cell cycle arrest or apoptosis
when administered at lower concentrations and induces
necrosis at higher concentrations, although the effect differs
between cell lines. Since CDDP exposure induces mitochon-
drial impairment and subsequently promotes cell death [38],
high levels of mitochondrial metabolic activity are expected
















































































































































































































































































































































































































































































































































































































































Figure 4: Combined treatment with melatonin and IR or CDDP increases oxidative stress in the HNSCC cell line Cal-27. Measurements of
intracellular ROS levels by fluorometry after staining with the DCF fluorescent probe (a, g), GPx activity (b, h), content of GSH (c, i) and
GSSG (d, j), GSSG/GSH ratio (e, k), and total glutathione (Gt) (f, l) in cells exposed to IR or CDDP, respectively. Treatment groups
include the control (vehicle), IR (8Gy), CDDP 10μM, melatonin (aMT) 1000 or 1500 μM, and CDDP or IR plus aMT 100, 500, 1000, or
1500μM. n = 6 per group. Data are presented as mean ± SEM. ∗P< 05, ∗∗P< 01, and ∗∗∗P< 001 vs. the control; #P< 05, ##P< 01, and
###P< 001 vs. the IR- or CDDP-treated group; δP< 05, δδP< 01, and δδδP< 001 vs. IR+aMT 100; $P< 05, $$P < 01, and $$$P < 001 vs. IR
+aMT 500.
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In order to mechanistically explain our findings, we
investigated the effect of the combined treatments on
mitochondrial respiration. We found that melatonin com-
bined with irradiation or CDDP increased ETS capacity
and ATP production. During late-stage apoptosis, ATP
levels declined, mainly due to mitochondrial function loss
and reduced consumption by ATP-dependent proteases
[39]. In line with this finding, we observed a decrease
in ATP levels following the combined treatment with
irradiation and melatonin 1500μM as compared to the
combined treatment with melatonin 500μM. These results
are consistent with the increase in apoptosis at melatonin
1500μM alone or combined with irradiation. However,
the combined treatment with melatonin and CDDP was
more toxic than that with irradiation. The occurrence of
ATP deprivation in all types of cell death suggests that
energy metabolism may play a critical role in cancer cell
survival under stress conditions. Thus, we demonstrate
that the strong antitumor effect of irradiation or CDDP
combined with melatonin is partly due to enhanced mito-
chondrial function.
Mitochondria also contain other molecules such as
mtDNA that can act as extracellular danger signals. In fact,
head and neck tumor cells lacking mtDNA become cisplatin
resistant [40]. Our results show that melatonin increases
mitochondrial mass and mtDNA copy number in a
dose-dependent manner and raises sensitivity to irradiation
and CDDP.
The release of mtDNA promotes the secretion of type I
interferon by malignant cells, which is necessary for the acti-
vation of optimal anticancer immune responses following
chemo- and radiation therapy [41]. Thus, mtDNA also acts
as a danger signal [42] linking intracellular stress responses
to the preservation of extracellular homeostasis [43].
In addition, autophagy is one of the principal mecha-
nisms involved in controlling cellular homeostasis [44,
45]. Although there is evidence to suggest that autophagy
has a prosurvival function, excessive autophagy may lead
to cell death, a process morphologically distinct from apo-
ptosis [46]. Moreover, autophagy-deficient malignant cells,
which succumb to in vivo chemotherapy and radiation
therapy, lose their ability to drive anticancer immunity
[9]. We detected increased expression of ATG12-ATG5,
which plays a critical role in the biogenesis and elongation
of the autophagosomal membrane following treatment with
high concentrations of melatonin combined with irradia-
tion or CDDP. However, NIX, which is required for the
selective mitophagy-dependent elimination of mitochon-
dria [47], only increased with high concentrations of
melatonin combined with CDDP. The role of mitophagy
in cancers is controversial. Mitophagy can facilitate sur-
vival through adaptation to stress, and mitophagic defects
also promote metastatic dissemination [48], most likely
due to moderate overproduction of ROS [49], which acti-
vate several signal transduction cascades associated with
metastatic dissemination [49]. Conversely, under severe oxi-
dative stress conditions, ROS de facto inhibit metastatic dis-
semination, most likely as a direct consequence of increased
apoptosis [50, 51].
Therefore, given that mitochondria are the main source
of cellular ROS, we hypothesize that melatonin enhances
the cytotoxic effects of irradiation and CDDP caused by
increased ROS production. Our study shows that melatonin
significantly increases intracellular ROS in cells exposed to
irradiation or CDDP. However, ROS production levels
increased following the combined treatment with CDDP
as compared to treatment with irradiation. Other research,
which reinforces our conclusions, has found that the
ROS-scavenging enzyme expression increases in CDDP-
resistant cancer cells as compared to normal cells and
that mitochondrial dysfunction may bestow resistance on
CDDP due to the absence of or reduction in mitochondrial
ROS responses [26].
The accumulation of intracellular ROS, which damages
organelle proteins, enzymes, and membranes, eventually
activates apoptosis signaling pathways [52]. ROS can also
cause cell death either directly or through activation of
intracellular proapoptotic pathways [52]. Besides triggering
apoptosis, oxidative stress can promote permanent prolifer-
ative arrest known as cellular senescence [53].
Increasing oxidative stress-targeting mitochondria is
therefore a novel therapeutic strategy for selectively killing
cancer cells. Our results clearly indicate that the potentiation
of the cytotoxic and proapoptotic effects of irradiation and
CDDP by melatonin is mediated, at least partially, by the
activation of mitochondrial function and subsequent over-
production of ROS in vitro in a dose-dependent manner.
Our data suggest that there is a correlation between the cell
content of melatonin and its apoptotic effects, thus support-
ing the notion that high concentrations of melatonin in
cancer cells are required to enhance the cytotoxic effect of
irradiation or CDDP.
A major limitation in the use of irradiation for thera-
peutic purposes is the development of side effects. Previous
studies have shown that melatonin not only enhances the
oncostatic effects of radio- and/or chemotherapy on tumor
cells but also protects normal cells against the adverse
effects of these treatments [18, 54–56]. We have patented
a melatonin gel to prevent mucositis, which has completed
a phase II clinical trial (EudraCT number: 2015-001534-13)
in 80 patients with head and neck cancer, and have demon-
strated that melatonin protects oral mucosa against the side
effects of radiotherapy. All these data show that melatonin
constitutes an innovative adjuvant strategy in the treatment
of cancer.
5. Conclusions
Our study suggests that high doses of melatonin sensitize
cancer cells to CDDP and irradiation by enhancing their
mitochondrial function. Melatonin is a ROS inducer in
HNSCC, and the accumulation of intracellular ROS plays
an upstream role in mitochondria-mediated apoptosis. Our
findings indicate that melatonin has great potential not only
in augmenting radio- and chemosensitivity to cisplatin and
other treatments but also in reducing toxicity caused by
radio- and chemotherapeutic agents in cancer patients.
Our study could provide a basis and guidelines for the
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application of treatment with melatonin combined with
radiotherapy or CDDP or other chemotherapeutic agents
to improve therapeutic efficiency for cancers, especially for
head and neck squamous cell carcinoma.
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